M Tortorella

Summary

Publications

  1. ncbi Will the real aggrecanase(s) step up: evaluating the criteria that define aggrecanase activity in osteoarthritis
    M D Tortorella
    Pfizer Global Research and Development, 700 Chesterfield Parkway, St Louis MO 60013, USA
    Curr Pharm Biotechnol 9:16-23. 2008
  2. ncbi Sites of aggrecan cleavage by recombinant human aggrecanase-1 (ADAMTS-4)
    M D Tortorella
    Departments of Inflammatory Diseases Research and Applied Biotechnology, DuPont Pharmaceuticals Company, Wilmington, Delaware 19880 0400, USA
    J Biol Chem 275:18566-73. 2000
  3. ncbi The thrombospondin motif of aggrecanase-1 (ADAMTS-4) is critical for aggrecan substrate recognition and cleavage
    M Tortorella
    Departments of Inflammatory Diseases Research and Applied Biotechnology, DuPont Pharmaceutical Company, Wilmington, Delaware 19880, USA
    J Biol Chem 275:25791-7. 2000
  4. ncbi Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors
    W Yao
    The DuPont Pharmaceuticals Company, Chemical and Physical Sciences, Inflammatory Diseases Research, Drug Metabolism and Pharmacokinetics Division, Experimental Station, Wilmington, Delaware 19880 0500, USA
    J Med Chem 44:3347-50. 2001
  5. ncbi Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins
    M D Tortorella
    Department of Inflammatory Diseases Research, DuPont Pharmaceuticals Company, Wilmington, DE 19880 0400, USA
    Science 284:1664-6. 1999
  6. ncbi Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family
    I Abbaszade
    Department of Applied Biotechnology, The DuPont Pharmaceuticals Company, Experimental Station, Wilmington, Delaware 19880, USA
    J Biol Chem 274:23443-50. 1999

Collaborators

  • R Newton
  • W Yao
  • C P Decicco
  • E C Arner
  • M A Pratta
  • I Abbaszade
  • H J George
  • R A Copeland
  • F Yang
  • J R Link
  • R Q Liu
  • S A Rosenfeld
  • O H Ross
  • M C Hillman
  • Y Itoh
  • K Murphy
  • J L Duke
  • R Wynn
  • T C Burn
  • B H Wiswall
  • H Nagase
  • R Bruckner
  • J M Hollis
  • R L Magolda
  • J M Trzaskos
  • D M Ellis

Detail Information

Publications6

  1. ncbi Will the real aggrecanase(s) step up: evaluating the criteria that define aggrecanase activity in osteoarthritis
    M D Tortorella
    Pfizer Global Research and Development, 700 Chesterfield Parkway, St Louis MO 60013, USA
    Curr Pharm Biotechnol 9:16-23. 2008
    ..Finally, using these criteria, we propose which ADAMTSs should be classified as aggrecanases and therefore be considered as drug targets for the development of chondroprotective OA treatments...
  2. ncbi Sites of aggrecan cleavage by recombinant human aggrecanase-1 (ADAMTS-4)
    M D Tortorella
    Departments of Inflammatory Diseases Research and Applied Biotechnology, DuPont Pharmaceuticals Company, Wilmington, Delaware 19880 0400, USA
    J Biol Chem 275:18566-73. 2000
    ..These data elucidate the sites and efficiency of cleavage during aggrecan degradation by aggrecanase and suggest potential tools for monitoring aggrecan cleavage in arthritis...
  3. ncbi The thrombospondin motif of aggrecanase-1 (ADAMTS-4) is critical for aggrecan substrate recognition and cleavage
    M Tortorella
    Departments of Inflammatory Diseases Research and Applied Biotechnology, DuPont Pharmaceutical Company, Wilmington, Delaware 19880, USA
    J Biol Chem 275:25791-7. 2000
    ..3) Aggrecanase-1 was not effective in cleaving glycosaminoglycan-free aggrecan. Taken together, these data suggest that the TSP-1 motif of aggrecanase-1 is critical for substrate recognition and cleavage...
  4. ncbi Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors
    W Yao
    The DuPont Pharmaceuticals Company, Chemical and Physical Sciences, Inflammatory Diseases Research, Drug Metabolism and Pharmacokinetics Division, Experimental Station, Wilmington, Delaware 19880 0500, USA
    J Med Chem 44:3347-50. 2001
    ..A cis-(1S)(2R)-amino-2-indanol scaffold was incorporated as a tyrosine mimic (P2') to conformationally constrain 2. Further optimization resulted in compound 11, a potent, selective, and orally bioavailable inhibitor of aggrecanase...
  5. ncbi Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins
    M D Tortorella
    Department of Inflammatory Diseases Research, DuPont Pharmaceuticals Company, Wilmington, DE 19880 0400, USA
    Science 284:1664-6. 1999
    ..The identification of this protease provides a specific target for the development of therapeutics to prevent cartilage degradation in arthritis...
  6. ncbi Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family
    I Abbaszade
    Department of Applied Biotechnology, The DuPont Pharmaceuticals Company, Experimental Station, Wilmington, Delaware 19880, USA
    J Biol Chem 274:23443-50. 1999
    ..Our findings will facilitate the study of the mechanisms of cartilage degradation and provide targets to search for effective inhibitors of cartilage depletion in arthritic disease...